(DCNF)—Senior Biden Food and Drug Administration (FDA) officials spent weeks casting doubt on reports of cardiac risks associated with the rollout of the COVID-19 vaccines to young adults and teenagers in the spring of 2021, according to a Senate report released Wednesday.
Among the officials named in the report is former FDA Center for Biologics Evaluation and Research Director Peter Marks — responsible for dubbing the mRNA COVID-19 vaccine development push “Operation Warp Speed”— who resigned from his post in March in opposition to what he described as Health and Human Services (HHS) Secretary Robert F. Kennedy Jr.’s “unprecedented assault on scientific truth,” particularly on vaccines.
But a new interim report by the Senate Homeland Security and Governmental Affairs’ Select Permanent Subcommittee on Investigations — which draws on 2,473 subpoenaed documents — raises questions about Marks’ own judgement on the COVID-19 vaccine and the judgement of other Biden administration officials.
The report chronicles how early warning signs for myocarditis and pericarditis — inflammation of the heart muscle or heart lining — were first communicated to the Centers for Disease Control and Prevention (CDC) by February 2021. Yet Marks and longtime FDA official Janet Woodcock raised doubts about the need to disseminate a formal warning in May 2021, the Senate committee’s report alleges.
The doubts of the FDA officials in May 2021 apparently prompted the CDC to “walk back” planned language for its website about the need to restrict exercise after myocarditis or pericarditis, according to the Senate report.
“The Biden administration’s decision to downplay the COVID-19 vaccine health risks and delay warning the public about cardiac-related adverse events associated with the mRNA vaccines jeopardized the public’s health,” the report alleges.
HHS turned over the documents in response to a January subpoena issued by Wisconsin Sen. Ron Johnson, finally responding to yearslong requests that were either ignored or barely answered under the Biden presidency.
Marks and Woodcock could not be reached for comment.
FDA recently ordered the drugmakers to expand the population covered by myocarditis and pericarditis warnings from males 18 to 24 years old for Moderna’s vaccine and 12 to 17 years old for Pfizer’s vaccine, as well as to males ages 16 to 25 for both products, CBS reported Wednesday, citing letters posted to the FDA website.”
Timeline
As early as Feb. 28, 2021, the Israeli Ministry of Health reached out to CDC to request a point of contact to discuss reports of myocarditis in young people receiving the COVID-19 vaccine, the report shows.
“The Israeli National Focal Point is noticing a large number of reports of myocarditis, particularly in young people, following the administration of the Pfizer vaccine,” an email obtained by the committee reads.
The ministry had seen about 40 cases mostly in people from 16 to 30 years old, a separate CDC email indicates, according to the committee’s report.
By April 21, 2021, a cardiovascular immunologist working with the U.S. Defense Health Agency warned public health officials about an association between myocarditis and the COVID-19 vaccines, documents obtained by the committee show.
The immunologist, Renata Engler, also warned that V-safe, a surveillance program to monitor the safety of COVID-19 vaccines that the CDC rolled out in December 2020, may not fully capture the prevalence of this side effect, the Senate report states.
Users of the V-safe app were asked if they experienced 10 symptoms ranging from muscle aches to nausea, but were not asked about symptoms that could signal a cardiac problem like chest pain, palpitations or shortness of breath, according to the Engler’s presentation, which was obtained by the committee.
“If you do not ask, you will not see it, but does that mean it does not exist?” her presentation reads, according to the committee’s report.
Engler did not respond to a request for comment.
By mid-May, momentum for a warning to be issued was building within CDC, the report shows: On May 14, 2021, CDC received notice that the European Medicines Agency had asked the pharmaceutical companies Pfizer and Moderna for more information about the risk of myocarditis and pericarditis. On May 17, 2021, the CDC’s advisers on the issue, the COVID-19 Vaccine Safety Technical Work Group, stated that members “felt that information about reports of myocarditis should be communicated to providers.”
By May 23, 2021, the Senate report shows, the CDC had drafted a formal notice to clinicians about myocarditis and pericarditis risk in young people through the Health Action Network or “HAN” with an expected release of May 25, 2021.
But on May 26, 2021, Woodcock alerted CDC Director Rochelle Walensky that “FDA does not concur with the issuance of the myocarditis HAN as written,” according to an email obtained by the committee.
The HAN was nixed the same day, other emails obtained by the committee indicate.
Walensky did not respond to a request for comment.
The CDC pivoted to less formal communication of the possible side effect through “clinical considerations” posted to its website, the report states.
But Marks raised doubts about even that less formal action being necessary, according to another email obtained by the committee.
“I need to ask for your patience with me,” Marks wrote on May 26, 2021. “We still have concerns here if myocarditis and pericarditis have not actually signaled.”
“Can you help me understand why we are doing this when pediatricians and others in the community already seem to be aware?” he continued.
The next day, internal emails obtained by the committee show that CDC official Demetre Daskalakis pared back the planned language for the CDC website about myocarditis.
“One language change around management and then we can move it forward,” Daskalakis wrote in the email. “They want to walk back this sentence: ‘Due to concerns for sudden cardiac events while the heart recovers, consider restricting patients with myocarditis from rigorous activity like competitive sports for at least 3 months until cleared by a healthcare professional.’”
Daskalakis did not respond to a request for comment.
On May 28, 2021, CDC posted its planned “clinical considerations” on its website about myocarditis and pericarditis, which did not contain the sentence about the risk of exercise and sports, the report states.
Another month would elapse before the FDA moved to change patient and provider fact sheets on the Pfizer and Moderna vaccines to include information about the risk of myocarditis and pericarditis on June 25, 2021.
“The full extent of the Biden administration’s failure to immediately warn the public about all COVID-19 vaccine adverse events must be completely exposed,” the committee’s report concludes.
All content created by the Daily Caller News Foundation, an independent and nonpartisan newswire service, is available without charge to any legitimate news publisher that can provide a large audience. All republished articles must include our logo, our reporter’s byline and their DCNF affiliation. For any questions about our guidelines or partnering with us, please contact [email protected].
Why Bullion Beats Numismatics and Collectible for Your Safe or IRA
Precious metals continue to attract Americans seeking reliable ways to protect their wealth amid inflation, geopolitical risks, and stock market swings. Whether stored in a home safe or held inside a self-directed IRA, physical gold and silver deliver tangible value that paper or digital assets often lack. Yet investors must choose carefully between bullion—pure bars and coins valued mainly for their metal content—and numismatics or collectibles, where rarity, history, and collector demand heavily influence pricing.
Advisor Bullion serves as a dependable source for straightforward, high-quality bullion. The company specializes in physical gold, silver, platinum, and palladium, emphasizing transparent pricing and products that deliver maximum metal content for every dollar spent. This approach makes it ideal for both personal holdings and retirement accounts.
Bullion consists of refined precious metals in standard forms like one-ounce coins (American Gold Eagles, Silver Eagles, Canadian Maple Leafs) or bars. Their value tracks closely to the current spot price of the metal. A typical gold bullion coin trades near the live gold spot price plus a small premium. This structure keeps costs clear and predictable.
Numismatic coins and collectibles add substantial value from factors such as age, rarity, minting errors, or historical significance. A pre-1933 U.S. gold coin or graded proof piece can carry premiums of 30%, 50%, or even 200% above melt value. While this appeals to hobbyists, it creates complexity. Pricing depends on subjective grading, collector trends, and auction results instead of daily spot prices.
For investors focused on wealth preservation and retirement security rather than building a collection, bullion often delivers better results.
Lower Costs and Better Liquidity for Home Storage
When keeping metals in a home safe or private vault, liquidity and efficiency count. Bullion offers clear benefits:
- You acquire more actual gold or silver per dollar invested. Numismatics divert a large share of your money into rarity premiums and massive sales commission, reducing your metal exposure.
- Selling bullion involves tight bid-ask spreads, so you recover nearly full spot value with minimal fees. Collectibles require finding the right buyer and may sell at a discount if demand for that specific item weakens.
- Bullion prices remain transparent and update with global spot markets. You can track gold near current levels or silver accordingly and know exactly where your holdings stand. Numismatic values are priced by the Gold IRA companies with hefty margins applied.
- Standardized coins and bars store efficiently and divide easily for partial sales. Rare coins often need protective slabs and controlled conditions, adding hassle and expense.
- Bullion enjoys worldwide acceptance. A 1-oz Gold Maple Leaf or Silver Eagle sells quickly to dealers anywhere. Niche numismatic pieces may appeal only to limited buyers, slowing liquidation when speed matters.
In times when quick access to value becomes important, bullion’s simplicity stands out.
Stronger Fit for Precious Metals IRAs
Precious metals IRAs continue gaining traction as investors diversify retirement portfolios beyond stocks and bonds. IRS rules permit certain bullion products in self-directed IRAs if they meet purity standards (.995 fine for gold, .999 for silver) and are held by an approved custodian. Eligible items include American Gold and Silver Eagles plus many generic bars and rounds from recognized mints.
Numismatic and most collectible coins generally face heavy scrutiny from custodians due to valuation disputes and elevated markups. These higher premiums mean less actual metal ends up working inside the account.
Bullion avoids these issues. Its value links directly to verifiable spot prices, which simplifies reporting and lowers the risk of regulatory challenges. More of your IRA contribution purchases real metal instead of dealer profits or speculative upside. Over time, owning additional ounces that appreciate with the metal itself can create meaningful outperformance compared with high-premium alternatives that deliver fewer ounces.
Regulatory guidance from the CFTC and state securities offices repeatedly cautions against aggressive sales of expensive numismatics or “semi-numismatic” coins for IRAs. For retirement planning, transparent bullion from established providers reduces risk and aligns better with long-term goals.
How to Get Started with Bullion
Begin by clarifying your goals. Are you protecting savings in a safe, or moving part of a retirement account into a precious metals IRA? Focus on the number of ounces you can acquire at current prices rather than chasing marked-up collectibles.
Diversify sensibly: use gold for core preservation and silver for its blend of industrial and monetary qualities. Mix coins for easier divisibility with bars for lower per-ounce costs on larger buys. Arrange secure storage—whether at home with proper insurance or through professional facilities.
As economic uncertainties linger and faith in conventional assets erodes, bullion continues proving its worth as a dependable store of value. Its direct approach avoids the hype that sometimes surrounds collectible markets and keeps the focus on the metal itself.
For investors prepared to strengthen their portfolios, Advisor Bullion supplies the expertise and selection needed to acquire high-quality bullion efficiently. Whether building personal holdings or integrating metals into an IRA, their emphasis on transparent, investment-grade products helps secure more ounces today that support greater financial security tomorrow. In a complicated financial landscape, bullion’s clarity and reliability make it the smarter foundation for protecting what matters most.